NEW YORK (GenomeWeb News) – Quest Diagnostics has struck multi-year agreements with both Illumina and Life Technologies to use their respective sequencing technologies for clinical testing, the firms said today.

Under two separate agreements, Quest will have the right to develop and offer molecular laboratory-developed tests using Illumina's MiSeq and Life Tech's Ion Torrent platforms and the respective related reagents for clinicians and clinical trials performed by its pharmaceutical and biotechnology clients.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.